Literature DB >> 14688365

Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G.

Nathalie Beaufort1, Dominique Leduc, Jean-Claude Rousselle, Viktor Magdolen, Thomas Luther, Abdelkader Namane, Michel Chignard, Dominique Pidard.   

Abstract

The urokinase receptor (CD87) participates to the pericellular proteolytic potential of migrating cells and to the recruitment of leukocytes during inflammation. It consists of three structurally homologous domains, with the C-terminal domain D3 attached to cell membranes through a GPI anchor. CD87 is susceptible to an endoproteolytic processing removing the N-terminal domain D1 and generating truncated D2D3 membrane species, thus modulating CD87-associated functions. Full-length or truncated CD87 can be also released from cells via juxtamembrane cleavage by phospholipases and/or by yet unidentified proteinases. Using a recombinant CD87 and the CD87-positive monocytic U937 cell line and isolated blood monocytes, we show by protein immunoblotting and flow immunocytometry that the human neutrophil serine-proteinases elastase and cathepsin G cleave CD87 within the D1-D2 linker sequence, while in addition cathepsin G is highly efficient in cleaving the C terminus of D3. The combination of cathepsin G and elastase provided by degranulated neutrophils results in enzymatic cooperation leading to the release from monocytic cells of a truncated D2D3 species resembling that previously described in pathological body fluids. Using mass spectrometry analysis, the proteolytic fragmentation of synthetic peptides mapping the D1-D2 linker and D3 C-terminal domains identifies potential cleavage sites for each enzyme and suggests the existence of a mechanism regulating the CD87(D1-D2)-associated chemotactic activity. Finally, isolated or combined elastase and cathepsin G drastically reduce the capacity of cells to bind urokinase. Secretable leukocyte serine-proteinases are thus endowed with high potential for the regulation of CD87 expression and function on inflammatory cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14688365     DOI: 10.4049/jimmunol.172.1.540

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Authors:  Evelyn C Nieves; Naveen Manchanda
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

2.  Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Authors:  Cyril Barinka; Graham Parry; Jennifer Callahan; David E Shaw; Alice Kuo; Khalil Bdeir; Douglas B Cines; Andrew Mazar; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

3.  Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation.

Authors:  Audrey M Bernstein; Sally S Twining; Debra J Warejcka; Edward Tall; Sandra K Masur
Journal:  Mol Biol Cell       Date:  2007-05-16       Impact factor: 4.138

Review 4.  Neutrophil serine proteases fine-tune the inflammatory response.

Authors:  Christine T N Pham
Journal:  Int J Biochem Cell Biol       Date:  2007-11-29       Impact factor: 5.085

5.  Identification of diagnostic biomarkers for infection in premature neonates.

Authors:  Stephen F Kingsmore; Neil Kennedy; Henry L Halliday; Jennifer C Van Velkinburgh; Shengiang Zhong; Vanessa Gabriel; Judith Grant; William D Beavis; Velizar T Tchernev; Lorah Perlee; Serguei Lejnine; Brian Grimwade; Martin Sorette; J David M Edgar
Journal:  Mol Cell Proteomics       Date:  2008-07-13       Impact factor: 5.911

Review 6.  Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor.

Authors:  Hernán Trimarchi
Journal:  World J Nephrol       Date:  2013-11-06

7.  Reproducibility of novel immune-inflammatory biomarkers over 4 months: an analysis with repeated measures design.

Authors:  Matthew Schenk; Fabian Eichelmann; Matthias B Schulze; Natalia Rudovich; Andreas F Pfeiffer; Romina di Giuseppe; Heiner Boeing; Krasimira Aleksandrova
Journal:  Biomark Med       Date:  2019-06-03       Impact factor: 2.851

8.  An agonist antibody that blocks autoimmunity by inducing anti-inflammatory macrophages.

Authors:  Kyung Ho Han; Rosana Gonzalez-Quintial; Yingjie Peng; Roberto Baccala; Argyrios N Theofilopoulos; Richard A Lerner
Journal:  FASEB J       Date:  2015-10-19       Impact factor: 5.191

9.  Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis.

Authors:  Boris K Pliyev; Mikhail Yu Menshikov
Journal:  Inflammation       Date:  2010-02       Impact factor: 4.092

10.  Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87).

Authors:  Boris K Pliyev
Journal:  Mol Cell Biochem       Date:  2008-10-02       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.